AFLIVIS 40 mg/ml sol inj 2 mg 1 pce

7680700610018 CH-70061 S01LA05 11.99.0.

Active substances:

Afliberceptum

No images available

Details

Product number
7006101
CPT
-
Packaging group
1
Unit
Durchstechflasche(n)
Composition
afliberceptum 2 mg, natrii acetas trihydricus, acidum aceticum glaciale, saccharum, natrii chloridum, polysorbatum 20, aqua ad iniectabile, ad solutionem pro 50 µl corresp. natrium 27 µg.

Articles (1)

Aflivis 40 mg/ml, Injektionslösung
Injektionslösung
1
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Professional SmPC
Allemand
29/05/2026
Professional SmPC
Français
29/05/2026
Professional SmPC
Italien
29/05/2026

Detailed composition

Substance Quantity Type Category
afliberceptum
2.0 MG Substance Wirkstoff (Principe actif)
natrii acetas trihydricus
- Substance HNIDK
acidum aceticum glaciale
- Substance HNIDK
saccharum
- Substance HNIDK
natrii chloridum
- Substance HNIDK
polysorbatum 20
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrium
27.0 UG Substance HBESI

Authorization holder

OmniVision AG

8212 Neuhausen am Rheinfall

Authorization information

Swissmedic authorization number
70061
Drug name
Aflivis, Injektionslösung
Galenic form
LSINJ
ATC Code
S01LA05
Authorization status
Z
Dispensation category
B
First authorization
02/02/2026
Authorization expiration date
01/02/2031
IT number
11.99.0.
Domain
Human medicine
Field of application
Exsudative (feuchte) altersbezogenen Makuladegeneration (AMD). Makulaödem infolge eines retinalen Zentralvenenverschlusses (CRVO) und retinalen Venenastverschlusses (BRVO), diabetisches Makulaödem (DME), Behandlung von subfovealen und juxtafovealen choroidalen Neovaskularisationen infolge einer pathologischen Myopie (mCNV).

Packaging details

Description (FR)
AFLIVIS 40 mg/ml sol inj 2 mg 1 pce
Description (DE)
AFLIVIS 40 mg/ml Inj Lös 2 mg 1 Stk
Market launch
01/10/2026
Narcotic (BTM)
No
Buy us a coffee Explore the data